SCYX

시간 외 거래: 3.58 0.01 +0.28%

Scynexis Inc (SCYX)

개요 뉴스 가격 이력 옵션 체인 Financials SCYX 왜 하락? 토론 예측 주식 분할

Relative Volume:

Scynexis Inc Stock (SCYX) Company Profile

Scynexis Inc

Healthcare (1074)

201-884-5485

1 EVERTRUST PLAZA, JERSEY CITY, NJ

최신 SEC 제출 서류

SCYX's Discussions on Twitter

Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
SCYX Scynexis Inc	3.57	37.04M	20.34M	-24.52M	-5.92M	-3.5761
TAK Takeda Pharmaceutical Co Adr	17.44	55.06B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.94	43.07B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.08	35.88B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.92	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	527.94	26.32B	3.17B	1.29B	1.01B	27.09

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-01-22	개시	Guggenheim	Buy
2021-01-06	개시	Cantor Fitzgerald	Overweight
2018-07-11	업그레이드	Needham	Hold → Buy
2018-06-27	개시	Maxim Group	Buy
2017-10-24	개시	Guggenheim	Buy
2017-07-10	개시	ROTH Capital	Buy
2017-05-09	다운그레이드	Needham	Buy → Hold
2017-03-03	재확인	RBC Capital Mkts	Outperform
2016-10-20	개시	H.C. Wainwright	Buy
2016-10-07	업그레이드	WBB Securities	Buy → Strong Buy
2016-10-03	재개	Brean Capital	Buy
2016-08-17	개시	Guggenheim	Buy
2016-08-09	재확인	Needham	Buy
2016-08-09	업그레이드	WBB Securities	Speculative Buy → Buy
2016-03-28	개시	Brean Capital	Buy
2015-12-29	개시	WBB Securities	Speculative Buy
2015-11-16	재확인	RBC Capital Mkts	Outperform
2015-06-10	개시	Needham	Buy
2014-05-29	개시	Canaccord Genuity	Buy
2014-05-29	개시	RBC Capital Mkts	Outperform

Scynexis Inc 주식(SCYX)의 최신 뉴스

Scynexis Inc (SCYX) 재무 분석

Scynexis Inc (SCYX)

Scynexis Inc Stock (SCYX) Company Profile

Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Scynexis Inc 주식(SCYX)의 최신 뉴스

SCYNEXIS Inc (SCYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

TradingKey - TradingKey

SCYNEXIS Inc (SCYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

SCYNEXIS, Inc. Revenue Breakdown – NASDAQ:SCYX - TradingView

SCYNEXIS, Inc. Revenue Breakdown – LSE:0L49 - TradingView

SCYNEXIS Inc (SCYX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

SCYNEXIS (SCYX) Slides 2.35% as Biotech Stock Tests Key Support LevelInsider Buying Alerts - dars.gov.et

Federated Hermes (SCYX) group discloses 4.03% Scynexis stake in amended 13G - Stock Titan

FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc - GuruFocus

Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%) - Stock Titan

Scynexis Deadline Alert - TMX Newsfile

Enterprise value to EBIT forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Enterprise value to EBIT forward of SCYNEXIS, Inc. – FWB:135 - TradingView

Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail

SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business - Sahm

Form DEF 14A Scynexis Inc For: 2 July By Investing.com - Investing.com Nigeria

Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained - TipRanks

Form 4 Scynexis Inc For: 30 June By Investing.com - Investing.com Nigeria

SCYNEXIS (SCYX) director receives new RSU and stock option grants - Stock Titan

SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards - Stock Titan

SCYNEXIS (SCYX) director Armando Anido granted stock units and options - Stock Titan

SCYNEXIS (SCYX) director receives new stock and option awards - Stock Titan

SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants - Stock Titan

Enterprise value to revenue forward of SCYNEXIS, Inc. – FWB:135 - TradingView

Scynexis (SCYX) Launches Phase 1 Study for SCY-770 in Kidney Dis - GuruFocus

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times

SCYNEXIS Inc. (SCYX) Q1 2026 Earnings: Wider-than-Expected Loss on No Reported Revenue; Stock Rises 5.17%EBITDA Analysis - dars.gov.et

Enterprise value to revenue forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Enterprise value to revenue forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Price to book forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Price to earnings forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Price to sales forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Price to book forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Enterprise value to EBITDA forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Price to sales forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Enterprise value to EBITDA forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

SCYNEXIS (SCYX) Edges Higher as Support Holds, Resistance AwaitsRetracement Entry - dars.gov.et

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes - TipRanks

SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale - Stock Titan

SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis - TradingKey

SCYNEXIS, Inc. Actuals & Estimates (NASDAQ:SCYX) - TradingView

SCYX Forecast — Price Target — Prediction for 2027 - TradingView

SCYNEXis (SCYX) Surges 6.6% – Testing Key Resistance at $4.25Low Beta Factor - dars.gov.et

SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

SCYNEXIS Inc (SCYX) Institutional Confidence - TradingKey

SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

SCYNEXIS Inc (SCYX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

SCYNEXIS (SCYX) Holds Near Support Amid Quiet TradingFast Moving Stocks - newsline.com

SCYNEXIS Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEPS Revision Trend - dars.gov.et

SCYNEXIS, Inc. Hits New 52-Week High of $5.62, Up 157.49% - MarketsMojo

Scynexis Inc (SCYX) 재무 분석

매출

순이익

현금흐름

주당 순 이익

SCYX과 유사한 종목